N-Acetyl Cysteine in Trichotillomania

University of Chicago50 enrolled

Overview

This is a 12-week, double-blind study of N-Acetyl Cysteine in the treatment of trichotillomania

The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine (NAC) in trichotillomania. Forty subjects with DSM-IV trichotillomania will receive 12 weeks of double-blind NAC or placebo. The hypothesis to be tested is that NAC will be effective and well tolerated in patients with trichotillomania compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Trichotillomania

Interventions

PlaceboDRUG

daily

N-Acetyl CysteineDRUG

600mg capsules in varying doses for 12 weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * men and women age 18-65; * current DSM-IV trichotillomania Exclusion Criteria: * unstable medical illness; * history of seizures; * myocardial infarction within 6 months; * current pregnancy or lactation, or inadequate contraception in women of childbearing potential; * any thoughts of suicide; * lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder; * previous treatment with N-Acetyl Cysteine; * treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline; * 9\) diagnosis of asthma

Locations (1)

University of Chicago Medical Center

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Massachusetts General Hospital Hairpulling Scale

There is no minimum or maximum score to quantify 'good' or 'poor' improvement based on this scale. The total score can range from 0-28 with zero being no problems to 28 being the most severe score one can receive.A total of 6 assessments were made, however only the final score (the score at the final visit after 12 weeks) was reported here to show the final outcome measure that was used in the final report of possible improvement and what was reported for final publication of data.

Time frame: Baseline and final visit after 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.